2019
DOI: 10.1007/s00432-019-02948-6
|View full text |Cite
|
Sign up to set email alerts
|

Effect of age on the effectiveness of the first-line standard of care treatment in patients with metastatic colorectal cancer: systematic review of observational studies

Abstract: Purpose Most metastatic colorectal cancer (mCRC) patients are elderly. This systematic review identifies and describes observational studies evaluating the influence of age on first-line treatment effectiveness in real-world practice. Methods Medline and EMBASE were searched up to May 2016. The included studies were those that investigated first-line treatment of mCRC and reported age groups and overall survival (OS), progression-free survival (PFS) or overall response … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
4
0

Year Published

2020
2020
2025
2025

Publication Types

Select...
5
1

Relationship

0
6

Authors

Journals

citations
Cited by 7 publications
(4 citation statements)
references
References 29 publications
0
4
0
Order By: Relevance
“…Thus, cluster B could also capture progression of cancer disease, particularly in metastatic setting, which may explain the impressive peak at 9 months. Indeed, the median progression free survival in the first line setting for metastatic cancer is ranging from 5 months to 10 months in lung, breast and colorectal cancers [ 20 , 21 , 22 ]. In addition, an overlap pathway between cancer-cachexia and frailty syndrome in the same cohort has previously been shown [ 23 ].…”
Section: Discussionmentioning
confidence: 99%
“…Thus, cluster B could also capture progression of cancer disease, particularly in metastatic setting, which may explain the impressive peak at 9 months. Indeed, the median progression free survival in the first line setting for metastatic cancer is ranging from 5 months to 10 months in lung, breast and colorectal cancers [ 20 , 21 , 22 ]. In addition, an overlap pathway between cancer-cachexia and frailty syndrome in the same cohort has previously been shown [ 23 ].…”
Section: Discussionmentioning
confidence: 99%
“…International treatment guidelines refer to inappropriate candidates for intensive therapy in general terms as those who will be unable to tolerate standard-dose combination therapy with a fluoropyrimidine + oxaliplatin or irinotecan, those for whom intensive treatment is not necessary and where the goal is disease control, and those refusing intensive treatment for personal reasons [4,7,8]. Categorization of patients with unresectable mCRC as candidates for intensive therapy is therefore a subjective decision-making process that relies on the treating physician's evaluation of suitability for therapy [10,12]. This represents a major challenge when selecting the most appropriate treatment option for patients with unresectable mCRC.…”
Section: Discussion and Future Perspectivesmentioning
confidence: 99%
“…Moreover, the definition of elderly (≥65, ≥70 or ≥75 years) differs in the published literature. Therefore, first-line treatment decisions for patients with unresectable mCRC should not be guided by age criteria alone, and should also take into account the patient's CGA results, PS, comorbidities, tumor characteristics, the extent of metastases and their own individual preferences [12,31,32]. In the SOLTSTICE study, the population of patients with low tumor burden mCRC may be defined as those with numerous small unresectable metastases, for example, CRC with numerous, but only, lung metastasis [33].…”
Section: Discussion and Future Perspectivesmentioning
confidence: 99%
See 1 more Smart Citation